Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Increases By 26.7%

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 53,600 shares, an increase of 26.7% from the February 28th total of 42,300 shares. Currently, 2.9% of the shares of the company are short sold. Based on an average daily volume of 66,000 shares, the days-to-cover ratio is currently 0.8 days.

Lixte Biotechnology Stock Down 0.5 %

LIXT traded down $0.01 on Tuesday, hitting $1.20. 971 shares of the company traded hands, compared to its average volume of 189,877. The stock has a market capitalization of $3.23 million, a PE ratio of -0.70 and a beta of 0.19. Lixte Biotechnology has a 12-month low of $1.02 and a 12-month high of $3.87. The company has a 50 day moving average of $1.67 and a 200-day moving average of $1.86.

Lixte Biotechnology (NASDAQ:LIXT) last released its earnings results on Monday, March 24th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. TIAA Trust National Association acquired a new position in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 101,834 shares of the company’s stock, valued at approximately $207,000. TIAA Trust National Association owned about 4.53% of Lixte Biotechnology as of its most recent filing with the Securities & Exchange Commission. 5.10% of the stock is currently owned by institutional investors and hedge funds.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.